MRK
REGN
The science miss turned into a legal headache
Regeneron disclosed on May 16th that its phase 3 trial of fianlimab plus Libtayo in first-line metastatic melanoma failed to hit the primary endpoint versus Merck’s Keytruda. That’s the kind of headline that can make a stock wobble on its own. But in biotech, a bad data readout sometimes comes with a second act: plaintiffs’ lawyers arriving like they saw the door left open.
Enter the investigators
Levi & Korsinsky says it’s looking into whether Regeneron may have run afoul of securities laws. Translation: they’re asking whether investors were given a rosier picture than the data deserved before the trial results hit the tape.
And yes, this is the classic biotech whiplash. One day you’re hoping a combo therapy becomes a blockbuster franchise. The next, the endpoint misses and the legal fax machine starts humming. Not exactly the glow-up management had in mind.
Why investors should care
This matters for two reasons:
- Sentiment gets uglier fast. A clinical disappointment is already a hit to the bull case; a securities probe can keep the stock under pressure longer.
- It adds uncertainty to the melanoma program. Even if the company can regroup scientifically, litigation noise can muddy the narrative and the valuation.
Big picture: Regeneron’s problem started in the lab, but now it’s making a pit stop in the courtroom. That’s rarely a great sign for the stock.